Results 21 to 30 of about 33,732 (139)

Effects of Remdesivir on in-Hospital and Late Outcomes of Patients With Confirmed or Clinically Suspected COVID-19: A Propensity Score-Matched Study

Acta Medica Iranica, 2022
Remdesivir, an antiviral medication, became an early promising therapeutic candidate for coronavirus disease 2019 (COVID-19) due to its ability to inhibit the virus in vitro. Current evidence about remdesivir treatment has been very controversial, so we
Azar Hadadi, Ali Ajam, Mahnaz Montazeri, Samira Kafan, Abdolazim Veisizadeh, Morteza Ghoghaei, Sina Kazemian, Arezoo Ahmadi, Fazeleh Majidi, Maryam Moghadasi, Mehdi Kashani, Faezeh Ghasemi, Marzieh Pazoki   +12 more
doaj   +1 more source

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

Clinical and Translational Science, 2022
On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID‐19), increasing remdesivir prescriptions worldwide.
Se Yong Jung, Min Seo Kim, Han Li, Keum Hwa Lee, Ai Koyanagi, Marco Solmi, Andreas Kronbichler, Elena Dragioti, Kalthoum Tizaoui, Sarah Cargnin, Salvatore Terrazzino, Sung Hwi Hong, Ramy Abou Ghayda, Nam Kyun Kim, Seo Kyoung Chung, Louis Jacob, Joe‐Elie Salem, Dong Keon Yon, Seung Won Lee, Karel Kostev, Ah Young Kim, Jo Won Jung, Jae Young Choi, Jin Soo Shin, Soon‐Jung Park, Seong Woo Choi, Kiwon Ban, Sung‐Hwan Moon, Yun Young Go, Jae Il Shin, Lee Smith   +30 more
doaj   +1 more source

An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)

Trials, 2021
Background Remdesivir is a novel broad-spectrum antiviral therapeutic with activity against several viruses that cause emerging infectious diseases.
Stephen I. Walimbwa, Julian P. Kaboggoza, Catriona Waitt, Pauline Byakika-Kibwika, Antonio D’Avolio, Mohammed Lamorde   +5 more
doaj   +1 more source

High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance

iScience, 2021
Summary: The use of remdesivir to treat COVID-19 will likely continue before clinical trials are completed. Due to the lengthening pandemic and evolving nature of the virus, predicting potential residues prone to mutation is crucial for the management of
Aditya K. Padhi, Rohit Shukla, Prakash Saudagar, Timir Tripathi   +3 more
doaj   +1 more source

Effect of remdesivir on mortality and the need for mechanical ventilation among hospitalized patients with COVID-19: real-world data from a resource-limited country

International Journal of Infectious Diseases, 2023
Objectives: Georgia introduced remdesivir for the treatment of COVID-19 in December 2020. We evaluated the real-world effect of remdesivir on mortality and the need for mechanical ventilation among inpatients with COVID-19.
Revaz Metchurtchlishvili, Nikoloz Chkhartishvili, Akaki Abutidze, Marina Endeladze, Marine Ezugbaia, Ana Bakradze, Tengiz Tsertsvadze   +6 more
doaj   +1 more source

Prominent bradycardia in a COVID-19 patient receiving Remdesivir: a case report

Qanun Medika: Jurnal Kedokteran Fakultas Kedokteran Universitas Muhammadiyah Surabaya, 2022
Remdesivir is a commonly used antiviral drug to treat COVID-19. Remdesivir has some side effects; however, whether it has any effect on cardiac is rarely reported.
Sidhi Laksono Purwowiyoto, Grace Trifena Hosea   +1 more
doaj   +1 more source

Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID‐19

Pharmacology Research & Perspectives, 2021
Both antiviral treatment with remdesivir and hemoadsorption using a CytoSorb® adsorption device are applied in the treatment of severe COVID‐19. The CytoSorb® adsorber consists of porous polymer beads that adsorb a broad range of molecules, including ...
Paul Biever, Dawid L. Staudacher, Michaela J. Sommer, Hannah Triebel, Merja A. Neukamm, Christoph Bode, Alexander Supady, Achim Lother   +7 more
doaj   +1 more source

Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition

Frontiers in Microbiology, 2020
Human enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy.
Wei Ye, Min Yao, Yangchao Dong, Chuantao Ye, Dan Wang, He Liu, Hongwei Ma, Hui Zhang, Libin Qi, Yuewu Yang, Yuan Wang, Liang Zhang, Linfeng Cheng, Xin Lv, Zhikai Xu, Yingfeng Lei, Fanglin Zhang   +16 more
doaj   +1 more source

Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing

Pharmaceutics, 2020
Remdesivir exhibits in vitro activity against SARS-CoV-2 and was granted approval for emergency use. To maximize delivery to the lungs, we formulated remdesivir as a dry powder for inhalation using thin film freezing (TFF).
Sawittree Sahakijpijarn, Chaeho Moon, John J. Koleng, Dale J. Christensen, Robert O. Williams   +4 more
doaj   +1 more source

Activation of the urotensin-II receptor by remdesivir induces cardiomyocyte dysfunction

Communications Biology, 2023
Remdesivir is an antiviral drug used for COVID-19 treatment worldwide. Cardiovascular side effects have been associated with remdesivir; however, the underlying molecular mechanism remains unknown.
Akiko Ogawa, Seiya Ohira, Yuri Kato, Tatsuya Ikuta, Shota Yanagida, Xinya Mi, Yukina Ishii, Yasunari Kanda, Motohiro Nishida, Asuka Inoue, Fan-Yan Wei   +10 more
doaj   +1 more source